drugset / Trial / NCT03385655
Prostate Cancer Biomarker Enrichment and Treatment Selection
Phase 2
Active not recruiting
200 enrolled
Canadian Cancer Trials Group
BC Cancer Foundation · collabCanadian Cancer Clinical Trials Network · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2024-10-07
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | 250 mg | — |
| Subject | Adavosertib | Small molecule | 300 mg | — |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Darolutamide | Other / unclassified | 600 mg | Oral |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Ipatasertib | Small molecule | 400 mg | — |
| Subject | OCIFISERTIB | Small molecule | 32 mg | — |
| Subject | Savolitinib | Small molecule | 600 mg | Oral |
| Subject | Tremelimumab | Monoclonal antibody | 225 mg | — |